-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E/5GP9PJJfamedknWtYIeKz+6uVDPlv9j9xLp51n2SnJgInmWC2Aibb/ExifE4By
 fZXLUVnv4WNAnA1ZvrRmxg==

<SEC-DOCUMENT>0000950117-00-000981.txt : 20000420
<SEC-HEADER>0000950117-00-000981.hdr.sgml : 20000420
ACCESSION NUMBER:		0000950117-00-000981
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20000419
ITEM INFORMATION:		
ITEM INFORMATION:		
FILED AS OF DATE:		20000419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		605014

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<DESCRIPTION>BRISTOL-MYERS SQUIBB COMPANY 8-K
<TEXT>




<PAGE>


                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934


                                 April 19, 2000
                Date of Report (Date of earliest event reported)


                          BRISTOL-MYERS SQUIBB COMPANY
             (Exact name of registrant as specified in its charter)

                                    Delaware
                 (State or other jurisdiction of incorporation)

<TABLE>
<S>                                          <C>
          1-1136                                       22-079-0350
(Commission File Number)                     (IRS Employer Identification No.)


         345 Park Avenue, New York                            10154
(Address of principal executive offices)                    (Zip Code)
</TABLE>

                                 (212) 546-4000
              (Registrant's telephone number, including area code)


<PAGE>


Item 5.  Other Events.

         Attached hereto and incorporated herein by reference as Exhibit 99.1 is
a copy of a press release issued by Bristol-Myers Squibb Company on April 19,
2000.


Item 7.  Financial Statements and Exhibits.

(c)      Exhibits

(99.1)   Press Release, dated April 19, 2000.


                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                         BRISTOL-MYERS SQUIBB COMPANY


                         By: /s/   Sandra Leung
                             -----------------------------------------------
                             Name:  Sandra Leung
                             Title: Secretary


Dated:    April 19, 2000


                                  EXHIBIT INDEX

                  (99.1) Press Release, dated April 19, 2000.








</TEXT>

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<DESCRIPTION>EXHIBIT 99.1
<TEXT>

<PAGE>



         (PRINCETON, N.J., April 19, 2000)--Bristol-Myers Squibb Company
(NYSE:BMY) is voluntarily withdrawing its current New Drug Application (NDA) for
VANLEV'TM' (omapatrilat) from the U.S. Food and Drug Administration (FDA). The
company now expects to resubmit its application early next year. Bristol-Myers
Squibb is taking this action in response to questions raised recently by the
agency regarding the comparative incidence and severity of an infrequent side
effect known as angioedema reported within the NDA database. Angioedema is a
localized swelling that generally affects the face, throat, lips or tongue that
can be triggered by food and commonly used drugs such as ACE-inhibitors,
nonsteroidal anti-inflammatory agents and some antibiotics.

         The company is cooperating with the FDA to identify the additional data
needed to resolve the agency's questions. Simultaneously, prospective controlled
clinical studies in patients with hypertension and heart failure will continue.
Regulatory filing activities outside the U.S. for VANLEV are proceeding as
planned.

         VANLEV is the most clinically developed member of the vasopeptidase
inhibitor class of cardiovascular compounds. VANLEV was designed to
simultaneously inhibit two key enzymes--angiotensin-converting enzyme (ACE) and
neutral endopeptidase (NEP)--which regulate blood pressure. Clinical studies
have demonstrated that VANLEV significantly reduces both systolic (top number)
and diastolic (bottom number) blood pressure.



<PAGE>

         In January 2000, the FDA provided a priority review for VANLEV, a
status the agency grants for drugs considered to be a significant therapeutic
advance under the Prescription Drug User Fee Act (PDUFA). VANLEV became the
first antihypertensive to receive a priority review under this system.

         Hypertension, or high blood pressure, affects more than 600 million
people worldwide. Three of four people with high blood pressure in the U.S. are
not at or below the recommended target goal of lower than 140/90 mmHg and remain
at higher risk for heart attack, stroke, heart failure, and kidney disease.
Bristol-Myers Squibb is committed to improving the lives of people with high
blood pressure and believes VANLEV will be a significant advance in extending
and enhancing human life.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
